MCID: ESP024
MIFTS: 58

Esophagitis

Categories: Gastrointestinal diseases, Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Esophagitis

MalaCards integrated aliases for Esophagitis:

Name: Esophagitis 11 53 43 14 71 75
Acute Esophagitis 11 71

Classifications:



External Ids:

Disease Ontology 11 DOID:11963
ICD9CM 34 530.1
MeSH 43 D004941
NCIt 49 C9224
SNOMED-CT 68 155673008
ICD10 31 K20
UMLS 71 C0014868 C0149882

Summaries for Esophagitis

MalaCards based summary: Esophagitis, also known as acute esophagitis, is related to peptic esophagitis and esophageal candidiasis, and has symptoms including pain in esophagus (finding) An important gene associated with Esophagitis is CCL26 (C-C Motif Chemokine Ligand 26), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Acetylsalicylic acid and Trimebutine have been mentioned in the context of this disorder. Affiliated tissues include smooth muscle, lung and spinal cord, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia: 75 Esophagitis, also spelled oesophagitis, is a disease characterized by inflammation of the esophagus. The... more...

Related Diseases for Esophagitis

Diseases in the Esophagitis family:

Bacterial Esophagitis Viral Esophagitis

Diseases related to Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 945)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 32.8 TNF IL1B HRH2 GAST CYP2C19 CXCL8
2 esophageal candidiasis 32.7 IL5 IL13 CYP2C19 CCL26 CAPN14
3 eosinophilic gastroenteritis 32.5 IL5 IL4 IL13 CCL26 CCL11
4 hernia, hiatus 32.0 HRH2 GAST CYP2C19
5 esophagitis, eosinophilic, 1 31.8 TSLP STAT6 PRG2 IL5 IL4 IL33
6 gastroesophageal reflux 31.5 TNF IL5 IL4 IL1B HRH2 GAST
7 ige responsiveness, atopic 31.4 STAT6 IL5 IL4 IL13
8 dyskinesia of esophagus 31.3 IL13 HRH2 CCL26 CAPN14
9 duodenal ulcer 31.2 TNF IL1B HRH2 GAST CYP2C19 CXCL8
10 gastric ulcer 31.2 HRH2 GAST CYP2C19
11 gastritis 31.2 TNF IL4 IL1B HRH2 GAST CYP2C19
12 peptic ulcer disease 31.1 TNF IL1B HRH2 GAST CYP2C19 CXCL8
13 chronic rhinitis 31.1 IL5 IL4 IL33 IL13
14 candidiasis 31.1 TNF IL5 IL4 IL1B CXCL8
15 atrophic gastritis 31.0 IL1B GAST CXCL8
16 hypereosinophilic syndrome 31.0 PRG2 IL5 IL4 IL13 CXCL8 CCR3
17 allergic rhinitis 30.8 IL5 IL4 IL13 CXCL8 CCR3 CCL11
18 systemic scleroderma 30.7 TNF IL4 IL1B IL13 CXCL8
19 pharyngitis 30.7 TNF IL1B CXCL8
20 crohn's disease 30.7 TNF IL5 IL4 IL1B IL13 CXCL8
21 food allergy 30.7 TSLP TNF STAT6 IL5 IL4 IL33
22 celiac disease 1 30.7 TSLP TNF IL5 IL4 IL1B IL13
23 stomatitis 30.5 TNF IL4 IL1B CXCL8
24 milk allergy 30.5 TSLP IL5 IL4 IL13
25 pollen allergy 30.5 IL5 IL4 IL13
26 gastroduodenitis 30.5 GAST CCL26
27 lichen planus 30.5 TNF IL4 IL1B FLG CXCL8
28 immune deficiency disease 30.4 TNF STAT6 IL4 IL1B IL13 CXCL8
29 laryngitis 30.4 TNF IL4 IL1B HRH2 CXCL8
30 paine syndrome 30.4 TNF IL1B CXCL8
31 irritable bowel syndrome 30.4 TNF IL4 IL1B CXCL8
32 glossitis 30.4 TNF IL1B GAST
33 gastroenteritis 30.4 TNF PRG2 IL5 IL4 IL1B HRH2
34 nasopharyngitis 30.4 TNF IL5 IL13
35 autoimmune disease 30.4 TNF IL5 IL4 IL1B IL13
36 bullous pemphigoid 30.4 TNF IL5 IL4 CXCL8 CCL11
37 allergic asthma 30.3 TSLP STAT6 IL5 IL4 IL13 CXCL8
38 bronchiectasis 30.3 TNF IL1B CXCL8
39 drug allergy 30.3 IL5 IL4 IL13 CYP2C19
40 aspiration pneumonia 30.3 TNF IL1B CXCL8
41 aphthous stomatitis 30.3 TNF IL1B CXCL8
42 neutropenia 30.3 TNF IL4 IL1B CXCL8
43 common cold 30.3 TSLP TNF IL5 IL4 IL33 IL1B
44 exanthem 30.3 TNF IL4 IL1B CXCL8
45 igg4-related disease 30.3 IL5 IL4 IL13
46 proteasome-associated autoinflammatory syndrome 1 30.2 TNF IL5 IL4 IL1B IL13 CXCL8
47 dermatitis 30.2 TSLP TNF IL5 IL4 IL33 IL1B
48 connective tissue disease 30.2 TNF IL5 IL4 IL1B IL13 CXCL8
49 bronchopneumonia 30.2 TNF IL1B CXCL8
50 acne 30.2 TNF IL1B FLG CXCL8

Comorbidity relations with Esophagitis via Phenotypic Disease Network (PDN): (show top 50) (show all 110)


Active Peptic Ulcer Disease Acute Cystitis
Acute Maxillary Sinusitis Acute Pancreatitis
Alcoholic Gastritis Allergic Rhinitis
Angina Pectoris Anxiety
Aortic Valve Disease 1 Atrophic Gastritis
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Cholecystitis Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Kidney Disease
Chronic Maxillary Sinusitis Chronic Pulmonary Heart Disease
Chronic Rhinitis Chylomicron Retention Disease
Conn's Syndrome Conversion Disorder
Cystitis Deficiency Anemia
Dependent Personality Disorder Dermatomycosis
Diabetic Polyneuropathy Duodenitis
Dyskinesia of Esophagus Dysthymic Disorder
Esophageal Cancer Esophageal Candidiasis
Esophageal Disease Esophageal Varix
First-Degree Atrioventricular Block Gallbladder Disease
Gastrin Secretion Abnormality Gastritis, Familial Giant Hypertrophic
Gastroesophageal Reflux Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Hepatitis Hyperlipoproteinemia, Type Iv
Hyperlipoproteinemia, Type V Hypertension, Essential

Graphical network of the top 20 diseases related to Esophagitis:



Diseases related to Esophagitis

Symptoms & Phenotypes for Esophagitis

UMLS symptoms related to Esophagitis:


pain in esophagus (finding)

MGI Mouse Phenotypes related to Esophagitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 CCL26 CCR3 GAST HRH2 IL13 IL1B
2 immune system MP:0005387 9.97 CCL11 CCR3 GAST IL13 IL1B IL33
3 digestive/alimentary MP:0005381 9.86 GAST HRH2 IL13 IL33 IL4 IL5
4 respiratory system MP:0005388 9.65 CCL11 CCR3 IL13 IL33 IL4 IL5
5 hematopoietic system MP:0005397 9.44 CCL11 CCL26 CCR3 IL13 IL1B IL33

Drugs & Therapeutics for Esophagitis

Drugs for Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
2
Trimebutine Approved Phase 4 39133-31-8 5573
3
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
4
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
5
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
6
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
7
Calcium polycarbophil Approved Phase 4 126040-58-2
8
Ondansetron Approved Phase 4 99614-02-5 4595
9
Bisacodyl Approved Phase 4 603-50-9 2391
10
Maleic acid Experimental, Investigational Phase 4 110-16-7, 110-17-8 444266 444972
11
Carnosine Experimental, Investigational Phase 4 305-84-0, 107667-60-7 439224
12
Indobufen Investigational Phase 4 63610-08-2 107641
13
Mosapride Investigational Phase 4 112885-41-3 119584
14 Anti-Inflammatory Agents Phase 4
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4
16 Parasympatholytics Phase 4
17 Antirheumatic Agents Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Analgesics Phase 4
20 Platelet Aggregation Inhibitors Phase 4
21 Fibrinolytic Agents Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Antipyretics Phase 4
24 Antioxidants Phase 4
25 Omeprazole, sodium bicarbonate drug combination Phase 4
26 Olive Phase 4
27
Cromolyn Sodium Phase 4
28 Serotonin Receptor Agonists Phase 4
29 Omega 3 Fatty Acid Phase 4
30 Cathartics Phase 4
31 Psyllium Phase 4
32 Laxatives Phase 4
33 Dermatologic Agents Phase 4
34 Psychotropic Drugs Phase 4
35 Antipsychotic Agents Phase 4
36 Anti-Anxiety Agents Phase 4
37
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
38
Esomeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6, 119141-88-7 9568614 4594
39
Rabeprazole Approved, Investigational Phase 3 117976-89-3, 117976-90-6 5029
40
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
41
Ranitidine Approved, Withdrawn Phase 3 66357-59-3, 82530-72-1, 66357-35-5 3001055 5039
42
Famotidine Approved Phase 3 76824-35-6 3325 5702160
43
Reslizumab Approved, Investigational Phase 2, Phase 3 241473-69-8
44
Povidone K30 Approved, Experimental Phase 3 9003-39-8 6917 131751496
45
Nizatidine Approved Phase 3 76963-41-2 3033637
46
Tegaserod Approved, Investigational, Withdrawn Phase 3 145158-71-0 5487301 135409453
47
Sucralfate Approved Phase 3 54182-58-0
48
Benralizumab Approved, Investigational Phase 3 1044511-01-4
49
Budesonide Approved Phase 3 51333-22-3 5281004 40000 63006
50
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030

Interventional clinical trials:

(show top 50) (show all 579)
# Name Status NCT ID Phase Drugs
1 The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
2 Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis Unknown status NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
3 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
4 Efficacy of Zinc L-carnosine (Hepilor®) in Maintaining Remission of Gastroesophageal Reflux Disease: a Randomised, Double-blind, Placebo-controlled Study Unknown status NCT03467438 Phase 4 Zinc-l-carnosine
5 Effect of Indobufen Versus Aspirin on Gastric Acid Secretion and Gastroesophageal Reflux in Patients With Coronary Heart Disease and Gastroesophageal Reflux Disease Undergoing Dual Antiplatelet Therapy: a Prospective, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Control Clinical Trials Unknown status NCT04129008 Phase 4 Indobufen and aspirin mimetic;Aspirin and indobufen mimetic
6 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
7 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
8 Vonoprazan Study In Patients With Erosive Esophagitis to Evaluate Long-term Safety: A Study to Evaluate the Safety of Long-term Administration of Vonoprazan in Maintenance Treatment in Patients With Erosive Esophagitis (EE) Completed NCT02679508 Phase 4 Vonoprazan;Lansoprazole
9 A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis. Completed NCT00641602 Phase 4 Esomeprazole;Lansoprazole
10 The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis Completed NCT01874535 Phase 4 Esomeprazole 40 mg
11 A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive. Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
12 A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
13 An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
14 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
15 Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease Completed NCT00872755 Phase 4
16 A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR) Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
17 Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
18 Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
19 An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
20 COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
21 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE) Completed NCT03116841 Phase 4 Vonoprazan
22 A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
23 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment Completed NCT00242736 Phase 4 Esomeprazole
24 A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis Completed NCT00133770 Phase 4 pantoprazole
25 Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed. Completed NCT00644735 Phase 4 Esomeprazole;Lansoprazole
26 Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age: A Randomized Controlled Trial Completed NCT02907632 Phase 4 Metoclopramide;Placebo
27 An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
28 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
29 Evaluation of Smectite Effect As A Food Thickener On Gastroesophageal Reflux Disease In Neonates Using Combined Esophageal Multichannel Intraluminal Impedance Completed NCT04788485 Phase 4 Diosmectite
30 The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT) Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole
31 A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00660660 Phase 4 Esomeprazole;Placebo
33 An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole
34 A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD) Completed NCT00216489 Phase 4 rabeprazole sodium
35 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
36 An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00626262 Phase 4 Esomeprazole
37 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: A Randomized Controlled Trial Completed NCT01093755 Phase 4 dexlansoprazole;Omeprazole
38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) Completed NCT00628342 Phase 4 Esomeprazole;Placebo
39 Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing Completed NCT00307944 Phase 4 Pantoprazole
40 CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD Completed NCT00325676 Phase 4 Pantoprazole
41 PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD Completed NCT00261339 Phase 4 Pantoprazole
42 Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids, a Double Blind Placebo Controlled Randomized Pilot Study Completed NCT01733147 Phase 4 Omega-3 polyunsaturated fatty acids;Placebo
43 Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week. Completed NCT00246909 Phase 4 Pantoprazole
44 Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease Completed NCT01882088 Phase 4 Mucofalk
45 A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole Completed NCT02351960 Phase 4 Dexlansoprazole
46 Effectiveness of Cycling of Topical Steroid Therapy in Maintaining Clinical and Histologic Remission in Eosinophilic Esophagitis Recruiting NCT05444543 Phase 4 Fluticasone Propionate;Budesonide
47 Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) Recruiting NCT04149470 Phase 4 Omeprazole 20mg BID
48 Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis Recruiting NCT05247866 Phase 4 Dupilumab
49 Examining the Effect of Ondansetron on Bowel Prep Success Recruiting NCT05439772 Phase 4 Ondansetron
50 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms

Search NIH Clinical Center for Esophagitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Esomeprazole
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
lansoprazole
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
pantoprazole
Pantoprazole sodium
Sucralfate

Cochrane evidence based reviews: esophagitis

Genetic Tests for Esophagitis

Anatomical Context for Esophagitis

Organs/tissues related to Esophagitis:

MalaCards : Smooth Muscle, Lung, Spinal Cord, Bone, Bone Marrow, Liver, Lymph Node

Publications for Esophagitis

Articles related to Esophagitis:

(show top 50) (show all 14495)
# Title Authors PMID Year
1
Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. 53 62
20208004 2010
2
Regulation of CDX2 expression in esophageal adenocarcinoma. 53 62
19415720 2009
3
Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis. 53 62
18844613 2008
4
[Eosinophilic esophagitis : a cause of dysphagia]. 53 62
18214405 2008
5
Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease. 53 62
17900656 2007
6
IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. 53 62
18073124 2007
7
Alterations in manganese superoxide dismutase expression in the progression from reflux esophagitis to esophageal adenocarcinoma. 53 62
17473952 2007
8
Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. 53 62
17059896 2006
9
CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation. 53 62
16868800 2006
10
Roles of epidermal growth factor and Na+/H+ exchanger-1 in esophageal epithelial defense against acid-induced injury. 53 62
16306134 2006
11
What is the best way to manage GERD symptoms in the elderly? 53 62
16510061 2006
12
Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. 53 62
16453027 2006
13
Lower prevalence of Helicobacter pylori infection with vacAs1a, cagA-positive, and babA2-positive genotype in erosive reflux esophagitis disease. 53 62
16302983 2005
14
Eosinophilic esophagitis. 53 62
16282772 2005
15
Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. 53 62
15884106 2005
16
The relationship between the esophageal tissue content of neurotensin and the presence or absence of esophageal inflammation. 53 62
14992433 2004
17
Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. 53 62
14724818 2003
18
Regulation of Na/H exchanger-1 in gastroesophageal reflux disease: possible interaction of histamine receptor. 53 62
14561010 2003
19
Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. 53 62
12560917 2003
20
Infiltrating eosinophils and eotaxin: their association with idiopathic eosinophilic esophagitis. 53 62
12392390 2002
21
Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation. 53 62
11474496 2001
22
The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori. 53 62
11403754 2001
23
Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. 53 62
11121210 2001
24
Plasmid/liposome transfer of the human manganese superoxide dismutase transgene prevents ionizing irradiation-induced apoptosis in human esophagus organ explant culture. 53 62
10900424 2000
25
Gastroesophageal reflux disease: pathophysiology and pharmacology overview. 53 62
10826019 2000
26
Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. 53 62
10492161 1999
27
Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance. 53 62
9165690 1996
28
Size reduction of gastric fundic gland polyposis by de-escalation of acid-suppressive therapy. 62
35898833 2023
29
Linked color imaging improves the diagnostic accuracy of eosinophilic esophagitis. 62
35898847 2023
30
A meta-analysis on randomized controlled trials of treating eosinophilic esophagitis with budesonide. 62
35862288 2022
31
Increased Prevalence of Eosinophilic Esophagitis in Patients With Chronic Rhinosinusitis. 62
36112756 2022
32
Role of mast cells in eosinophilic esophagitis. 62
36165008 2022
33
Eosinophilic Esophagitis: The Role of Environmental Exposures. 62
36265974 2022
34
Objectively confirmed gastroesophageal reflux disease and risk of atrial fibrillation: a population-based cohort study in Sweden. 62
36052701 2022
35
Marked improvement of severe reflux esophagitis following proximal gastrectomy with esophagogastrostomy by the right gastroepiploic vessels-preserving antrectomy and Roux-en-Y biliary diversion. 62
35796810 2022
36
Network pharmacology-based prediction and verification of the active ingredients and potential targets of Huagan Decoction for reflux esophagitis. 62
35988839 2022
37
Induction and maintenance of healing in erosive esophagitis in the United States. 62
36254610 2022
38
L-Arginine Supplement-Induced Esophagitis in an Adolescent Boy. 62
36200327 2022
39
[Somatostatin-analogue treatment of severe esophagitis after gastrectomy]. 62
35925123 2022
40
Linear- versus circular-stapled esophagogastric anastomosis during esophagectomy: systematic review and meta-analysis. 62
36242619 2022
41
A 3-year follow-up study of uncut Roux-en-Y reconstruction: clinical results and outcomes. 62
35380283 2022
42
Esophageal Intramural Pseudodiverticulosis Diagnosed by Combining Esophagogastroduodenoscopy, Esophagography, and High-resolution manometry: A Case Report. 62
36223924 2022
43
Prevention and management of acute esophageal toxicity during concomitant chemoradiotherapy for locally advanced lung cancer. 62
34165018 2022
44
VONOPRAZAN VERSUS LANSOPRAZOLE FOR HEALING AND MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS: A RANDOMIZED TRIAL. 62
36228734 2022
45
Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China. 62
35994227 2022
46
The clinical outcome of postoperative radiotherapy using hybrid planning technique in left breast cancer after breast-conserving surgery. 62
36250354 2022
47
Is single tract jejunal interposition better than double tract reconstruction after proximal gastrectomy? 62
36208365 2022
48
Mid-Term and Long-Term Outcomes of Peroral Endoscopic Myotomy for the Treatment of Achalasia: A Systematic Review and Meta-Analysis. 62
36260203 2022
49
An unexpected cause of colitis. 62
35811349 2022
50
A Retrospective Study of the Differences in the Induction of Regulatory T Cells Between Adult Patients with Eosinophilic Esophagitis and Gastroesophageal Reflux Disease. 62
35031876 2022

Variations for Esophagitis

Expression for Esophagitis

Search GEO for disease gene expression data for Esophagitis.

Pathways for Esophagitis

Pathways related to Esophagitis according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 TSLP TNF STAT6 SOD2 PRG2 IL5
2
Show member pathways
13.79 TNF STAT6 PRG2 IL5 IL4 IL1B
3 13.74 TNF STAT6 IL5 IL33 HRH2 GAST
4
Show member pathways
13.61 CCL11 CCL26 CCR3 CXCL8 IL13 IL1B
5
Show member pathways
13.52 CCL11 CCL26 CXCL8 IL13 IL1B IL4
6
Show member pathways
13.38 TNF STAT6 IL5 IL4 IL1B IL13
7
Show member pathways
13.28 CCL11 CXCL8 IL13 IL1B IL33 IL4
8
Show member pathways
13.27 TNF IL5 IL4 IL1B IL13 CXCL8
9
Show member pathways
12.62 TNF STAT6 IL5 IL4 IL1B IL13
10
Show member pathways
12.43 IL4 IL33 IL1B IL13
11
Show member pathways
12.41 TNF IL4 IL1B CXCL8 CCL11
12
Show member pathways
12.39 IL5 IL1B IL13 CAPN14
13
Show member pathways
12.31 CXCL8 CCR3 CCL26 CCL11
14 12.15 TNF IL1B IL13 CXCL8
15 12.1 IL13 IL1B IL4 STAT6 TNF
16
Show member pathways
12.05 CXCL8 CCR3 CCL26 CCL11
17 12 TNF IL5 IL4 CCR3
18 11.99 TNF IL4 IL1B CXCL8
19 11.9 CCL11 CXCL8 IL13 IL1B IL4 STAT6
20 11.85 TNF IL5 IL4 IL1B IL13 CXCL8
21 11.79 CXCL8 IL13 IL4 IL5
22 11.77 TNF IL1B FLG CXCL8
23
Show member pathways
11.71 TNF IL5 IL4 CXCL8
24 11.69 STAT6 IL4 IL1B
25 11.69 STAT6 IL5 IL4 CCL26 CCL11
26 11.68 IL5 IL4 CXCL8
27
Show member pathways
11.66 TNF STAT6 IL5 IL4 IL13
28
Show member pathways
11.64 CXCL8 IL1B TNF
29 11.6 TSLP TNF IL5 IL4 IL33 IL1B
30 11.5 TNF IL1B CXCL8
31 11.4 STAT6 IL5 IL4 IL33 IL13 CCL11
32 11.3 TNF IL1B CXCL8
33 11.25 TNF IL1B CXCL8
34 11.23 TNF IL5 IL4 IL1B IL13
35 11.21 IL5 IL4 IL13
36 11.02 TNF IL5 IL4 IL1B IL13 CXCL8
37 11 TSLP TNF IL5 IL4 IL33 IL1B
38 10.99 TNF PRG2 IL5 IL4 IL1B IL13
39 10.86 IL5 IL4 IL1B IL13
40
Show member pathways
10.36 TNF CXCL8

GO Terms for Esophagitis

Cellular components related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10 TSLP TNF IL5 IL4 IL33 IL1B
2 extracellular region GO:0005576 9.68 CCL11 CCL26 CXCL8 GAST IL13 IL1B

Biological processes related to Esophagitis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.41 TNF IL4 IL33 IL1B IL13 CXCL8
2 positive regulation of cell migration GO:0030335 10.29 SOD2 IL4 IL1B CCL26 CCL11
3 chemotaxis GO:0006935 10.23 CCL11 CCL26 CCR3 CXCL8
4 response to lipopolysaccharide GO:0032496 10.18 TNF SOD2 IL1B IL13
5 positive regulation of inflammatory response GO:0050729 10.17 IL1B IL33 TNF TSLP
6 positive regulation of interleukin-6 production GO:0032755 10.16 TSLP TNF IL33 IL1B
7 positive regulation of B cell proliferation GO:0030890 10.1 IL5 IL4 IL13
8 positive regulation of nitric oxide biosynthetic process GO:0045429 10.09 TNF SOD2 IL1B
9 positive regulation of interleukin-10 production GO:0032733 10.08 IL13 IL4 TSLP
10 neutrophil chemotaxis GO:0030593 10.06 IL1B CXCL8 CCL26 CCL11
11 inflammatory response GO:0006954 10.06 TNF IL5 IL1B IL13 CXCL8 CCR3
12 chemokine-mediated signaling pathway GO:0070098 10.03 CCL11 CCL26 CCR3 CXCL8
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.01 TSLP TNF IL4 IL13
14 positive regulation of immunoglobulin production GO:0002639 9.99 IL13 IL33 IL5
15 signal transduction GO:0007165 9.98 CCL11 CCL26 CCR3 CXCL8 GAST HRH2
16 response to radiation GO:0009314 9.97 TNF SOD2 CCL11
17 microglial cell activation GO:0001774 9.97 TNF IL4 IL13
18 type 2 immune response GO:0042092 9.95 IL4 IL33
19 negative regulation of neurogenesis GO:0050768 9.95 TNF IL1B CCL11
20 vascular endothelial growth factor production GO:0010573 9.94 TNF IL1B
21 positive regulation of mononuclear cell migration GO:0071677 9.92 TNF IL4
22 positive regulation of fever generation GO:0031622 9.9 TNF IL1B
23 sequestering of triglyceride GO:0030730 9.88 TNF IL1B
24 positive regulation of chemokine production GO:0032722 9.87 TSLP TNF IL33 IL1B
25 negative regulation of complement-dependent cytotoxicity GO:1903660 9.85 IL4 IL13
26 positive regulation of interleukin-13 production GO:0032736 9.85 TSLP IL4 IL33
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.84 TNF IL1B
28 positive regulation of isotype switching to IgE isotypes GO:0048295 9.83 STAT6 IL4
29 positive regulation of neuroinflammatory response GO:0150078 9.73 IL1B IL33 TNF
30 immune response GO:0006955 9.58 TNF PRG2 IL5 IL4 IL1B IL13

Molecular functions related to Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.63 CXCL8 CCL26 CCL11
2 cytokine activity GO:0005125 9.55 TSLP TNF IL5 IL4 IL33 IL1B
3 CCR3 chemokine receptor binding GO:0031728 9.26 CCL26 CCL11

Sources for Esophagitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....